The future of medicine lies within us.
We are an in vivo hematopoietic stem cell (HSC) engineering company.
Ensoma’s platform revealed
We are creating a new kind of genomic medicine for patients around the world.
Our platform is an in vivo hematopoietic stem cell (HSC) engineering technology. It combines an off-the-shelf, in vivo system that delivers a gene engineering toolkit. The HSC engineering platform is designed to selectively and durably modify cells of the hematopoietic system with the intent to treat diseases with unprecedented versatility – all with a one-time treatment regimen.
A vision for the patient journey
The patient experience is a crucial part of treatment. We aim to shape a new experience defined by simplicity, speed and safety.
Excited by our bold vision to bring forth a new kind of medicine?
